NDC 70710-1401-01 - CLOBETASOL PROPIONATE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70710-1401
- Requested NDC
- 70710-1401-01
- Package NDCs from labels
- 70710-1401-1, 70710-1401-2, 70710-1401-4, 70710-1401-3, 70710-1401-01
- Manufacturer
- Zydus Pharmaceuticals USA Inc. | Zydus Lifesciences Limited
- Effective date
- 2022-10-05
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| CLOBETASOL - Zydus Pharmaceuticals USA Inc. | Zydus Lifesciences Limited | Zydus Pharmaceuticals USA Inc. | Zydus Lifesciences Limited | 2022-10-05 | HUMAN PRESCRIPTION DRUG LABEL |
| CLOBETASOL PROPIONATE OINTMENT USP, 0.05% | Preferred Pharmaceuticals, Inc. | 2022-04-19 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70710-1401-1 | CLOBETASOL PROPIONATE | 1 in 1 CARTON | OINTMENT | 1 | 6 | |
| 70710-1401-1 | CLOBETASOL PROPIONATE | 15 g in 1 TUBE | OINTMENT | 15 | 6 | |
| 70710-1401-2 | CLOBETASOL PROPIONATE | 1 in 1 CARTON | OINTMENT | 1 | 6 | |
| 70710-1401-2 | CLOBETASOL PROPIONATE | 30 g in 1 TUBE | OINTMENT | 30 | 6 | |
| 70710-1401-3 | CLOBETASOL PROPIONATE | 60 g in 1 TUBE | OINTMENT | 60 | 6 | |
| 70710-1401-3 | CLOBETASOL PROPIONATE | 1 in 1 CARTON | OINTMENT | 1 | 6 | |
| 70710-1401-4 | CLOBETASOL PROPIONATE | 45 g in 1 TUBE | OINTMENT | 45 | 6 | |
| 70710-1401-4 | CLOBETASOL PROPIONATE | 1 in 1 CARTON | OINTMENT | 1 | 6 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 70710-1401 | CLOBETASOL PROPIONATE OINTMENT [ZYDUS PHARMACEUTICALS USA INC.] | 6 | Current NDC, Legacy NDC, 8 package rows | 20221007_98a25409-e84e-452b-8dc5-ad87842398e1.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 70710-1401-1 | GM - Gram | 70710-1401 | dca331a7-bcc8-4f19-a9f3-51fed30ef500 | 1 | 2019-04-11 |
| 70710-1401-2 | GM - Gram | 70710-1401 | 2d156802-6d97-4fa4-82fd-eefd8cfb2731 | 1 | 2019-04-11 |
| 70710-1401-3 | GM - Gram | 70710-1401 | abe4f473-b54e-44c6-b448-6ea1d8959a62 | 1 | 2019-04-11 |
| 70710-1401-4 | GM - Gram | 70710-1401 | 8d5330df-ae86-45ca-9c89-e40f20dda0ff | 1 | 2019-04-11 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Baby Petrolatum Jelly | PETROLATUM | SHIELD LINE LLC | 35c163e6-ae41-2791-e054-00144ff8d46c | 2025-08-15 | Warnings | 4T6H12BN9U |
| Clobetasol Propionate | CLOBETASOL PROPIONATE | Xiromed, LLC | 2556987f-4b0f-8a83-5bf4-095d67a450b4 | 2025-08-12 | Adverse reactions | 779619577M |
| DG Health Hemorrhoidal | MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL | Dolgencorp, LLC | d9f12a34-7bd1-4ba5-b34b-1b641f58271a | 2025-08-12 | Warnings | 4T6H12BN9U |
| Stye | MINERAL OIL AND PETROLATUM | Insight Pharmaceuticals LLC | f7eb8466-d8ea-4833-9bed-244ead38a3bf | 2025-08-11 | Warnings | 4T6H12BN9U |
| Norms Hemorrhoid | GLYCERIN, LIDOCAINE, PETROLATUM, PHENYLEPHRINE HCL | Totally Normal Company | 3bdf8c74-3db6-1805-e063-6394a90aaba0 | 2025-08-08 | Warnings | 4T6H12BN9U |
| Systane COMPLETE | PROPYLENE GLYCOL | Alcon Laboratories, Inc. | 2df0de02-a3e2-471a-9e10-040c3fba75fe | 2025-08-08 | Warnings | 6DC9Q167V3 |
| Systane Balance | PROPYLENE GLYCOL | Alcon Laboratories, Inc. | c7b1a03a-a5f2-409e-a34a-d6f166671de5 | 2025-08-07 | Warnings | 6DC9Q167V3 |
| Clobetasol Propionate Cream 0.05% Clobetasol Propionate Cream 0.05% | CLOBETASOL PROPIONATE CREAM 0.05% | Preferred Pharmaceuticals Inc. | 1917a2a1-1591-4383-8466-ae12988b209f | 2025-08-01 | Adverse reactions | 779619577M |
| EA EIGHT HOUR SKIN PROTECTANT | PETROLATUM | REVLON | b590991c-8ec8-67c2-e053-2a95a90a3acf | 2025-08-01 | Warnings | 4T6H12BN9U |
| EIGHT HOUR SKIN FRAGRANCE FREE | PETROLATUM | REVLON | b61d6e2e-18dd-37d2-e053-2a95a90af57b | 2025-08-01 | Warnings | 4T6H12BN9U |
| Asteroid | MENTHOL, PETROLATUM, ZINC OXIDE | HEALTHTEX LIMITED | 29d1e46d-0189-4f9e-9963-8a9de2757f28 | 2025-07-30 | Warnings | 4T6H12BN9U |
| Systane Ultra | POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL | Alcon Laboratories, Inc. | 0537c23a-15f7-be64-1231-a6c93468e9a8 | 2025-07-30 | Warnings | 6DC9Q167V3 |
| Systane | POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL | Alcon Laboratories, Inc. | 1d679d0f-cec2-a644-79cd-079607254bb9 | 2025-07-30 | Warnings | 6DC9Q167V3 |
| Systane Ultra Preservative Free | POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL | Alcon Laboratories, Inc. | 751fb85f-6683-4b0a-a650-324d4a74c5de | 2025-07-30 | Warnings | 6DC9Q167V3 |
| Systane COMPLETE PF | PROPYLENE GLYCOL | Alcon Laboratories, Inc. | 99b63d62-1cf0-4f28-8760-773917c2538a | 2025-07-29 | Warnings | 6DC9Q167V3 |
| ProCure SkinGuard | PETROLATUM 49.9% | Twin Med LLC | 3a1721f6-1bb0-cd47-e063-6394a90a148e | 2025-07-25 | Warnings | 4T6H12BN9U |
| ProCure HydroCerin | PETROLATUM 33% | Twin Med LLC | 3ab7248d-b914-9fdd-e063-6294a90ac4c8 | 2025-07-24 | Warnings | 4T6H12BN9U |
| AD PREVENT Original | AD PREVENT ORIGINAL | WellSpring Pharmaceutical Corporation | cf73246e-81c1-42e9-a107-dc6c99cf7d01 | 2025-07-24 | Warnings | 4T6H12BN9U |
| Dr Butlers Soothing Incontinence | MINERAL OIL 59.8%, PETROLATUM 36.0% | Beyond Health PA | 3a9d3796-fd05-fe57-e063-6294a90a0ac6 | 2025-07-23 | Warnings | 4T6H12BN9U |
| A and D plus E | VITAMIN A, D AND E OINTMENT | Derma Sciences Canada Inc. | 35aca592-bfd0-652f-e063-6394a90ac53e | 2025-07-22 | Warnings | 4T6H12BN9U |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.